A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

EMD Serono Inc., Merck KGaA’s North American drug development business, has officially taken up residence in Boston’s Seaport ...

Stop by Bell Tower at 520 Main Avenue Sept. 9 - 13 to meet members of the Bell team and register for prizes. Bell Bank is seen on Wednesday, Sept. 4, 2024, located on Main Avenue in downtown Fargo ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

“They’re miraculous when they work.” Developed by Bristol Myers Squibb, Opdivo was the second so-called PD1 inhibitor to be approved in the U.S. The first, Merck & Co.’s Keytruda, won Food and Drug ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Unilever — the massive consumer goods company — is moving its North American headquarters to Hoboken next year, a real estate developer announced this week. The company’s headquarters have ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.